Taiho Pharmaceutical and Cullinan Oncology Establish Collaboration to Develop TAS6417, Novel EGFR Ty


-FIH Study in EGFR Exon 20 Insertions Will Commence in 2019- TOKYO and CAMBRIDGE, Massachusetts, Feb. 5, 2019 /PRNewswire/ -- Taiho Pharmaceutical Co., Ltd. ... Lees verder

Bron: ANP Pers support
Geplaatst: 05 feb 2019 - 09:01